Developing a consensus statement for psychosocial support in active surveillance for prostate cancer.
Delphi study
active surveillance
consensus statement
prostatic neoplasms
psychosocial support systems
Journal
BJUI compass
ISSN: 2688-4526
Titre abrégé: BJUI Compass
Pays: United States
ID NLM: 101764975
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
entrez:
26
12
2022
pubmed:
27
12
2022
medline:
27
12
2022
Statut:
epublish
Résumé
Our objective was to prioritise the psychosocial support needs of men on active surveillance for prostate cancer and to develop a consensus statement to provide guidance on best practice psychosocial support for men choosing active surveillance and their families. We undertook a patient and public involvement Delphi process over two rounds, informed by qualitative data and a comprehensive literature review, to prioritise the information and support needs of men on active surveillance for prostate cancer. Two panels were surveyed, a patient/carer panel ( Patients and health care professionals differed slightly in their ideas concerning priorities for active surveillance psychosocial support. Broadly, agreed priority areas included -patients being involved in decision-making, continuity of care, more streamlined access to health care teams, improved understanding of the risk of prostate cancer progression and information and support provided through both health care professionals and peers. Based on the identified priorities, the expert discussion group agreed on 22 consensus statements for best practice in psychosocial care for active surveillance in respect of (1) principles of an active surveillance programme; (2) structure of consultations; (3) content of information and support; and (4) delivery of information. This consensus statement provides a framework for patient-focused psychosocial support, which, if adopted, should increase uptake and adherence to active surveillance among men with prostate cancer.
Identifiants
pubmed: 36569508
doi: 10.1002/bco2.155
pii: BCO2155
pmc: PMC9766868
doi:
Types de publication
Journal Article
Langues
eng
Pagination
104-113Informations de copyright
© 2022 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company.
Déclaration de conflit d'intérêts
All authors declare no conflicts of interest.
Références
BJU Int. 2019 Jul;124(1):47-54
pubmed: 30742733
BMC Urol. 2021 Feb 4;21(1):18
pubmed: 33541309
BJU Int. 2012 Jul;110(2 Pt 2):E50-6
pubmed: 22145791
Transl Androl Urol. 2018 Feb;7(1):83-97
pubmed: 29594023
BMJ Open. 2015 Sep 18;5(9):e008953
pubmed: 26384727
BJU Int. 2007 Sep;100(3):544-51
pubmed: 17532857
Cancer Nurs. 2005 Mar-Apr;28(2):99-107
pubmed: 15815179
Med Care Res Rev. 2013 Dec;70(6):567-96
pubmed: 23894060
Int J Obes (Lond). 2019 Dec;43(12):2573-2586
pubmed: 30655580
Qual Health Res. 2009 Apr;19(4):432-43
pubmed: 19229061
J Health Serv Res Policy. 2009 Oct;14(4):226-33
pubmed: 19770121
Res Involv Engagem. 2018 Jun 25;4:19
pubmed: 29983994
Eur Urol. 2018 Sep;74(3):261-280
pubmed: 29598981
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
Patient. 2014;7(4):427-36
pubmed: 24920082
Transl Androl Urol. 2021 Jun;10(6):2728-2736
pubmed: 34295758
Int J Clin Pharm. 2016 Jun;38(3):655-62
pubmed: 26846316